<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) July 16, 1996
------------------
BOSTON LIFE SCIENCES, INC.
---------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-6533 87-0277826
--------------- ------ ----------------
(State or other jurisdiction of (Commission (I.R.S. Employer Identification
incorporation or organization) File No.) No.)
33 Newbury Street, Suite 300
Boston, Massachusetts 02116
- ----------------------------- -----------
(Address of principal executive offices) Zip Code
Registrant's telephone number, including area code (617) 425-0200
---------------------
-1-
<PAGE>
Item 5. Other Events.
------------
On July 16, 1996, Boston Life Sciences, Inc., a company engaged in the
research and development of novel treatments for cancer, autoimmune diseases,
and central nervous systems disorders announced that the Company had completed a
physician-sponsored Phase I/II study on the Company's Parkinson's Disease
diagnostic agent, Altropane. In the Phase I portion of the study, Altropane
was administered to ten healthy normal volunteers in order to determine safety
and brain image quality. The Phase II portion of the study was designed to test
Altropane's ability to detect changes in the number of dopamine transporters in
the brain in nine patients with clinically diagnosed Parkinson's Disease. The
study was carried out at the Massachusetts General Hospital under the auspices
of Dr. Alan Fishman, chief of nuclear medicine at the MGH.
The results from this study indicate that Altropane is a safe,
accurate and convenient agent to image the dopamine transporter system in the
brain. Results from this study showed that the use of Altropane together with
SPECT brain scanning demonstrated a greater than 70% loss of dopamine
transporters in patients with mild clinical disease, while patients with more
severe disease were shown to have had an even greater loss. In one patient in
whom the diagnosis of Parkinson's Disease was in dispute, physicians in the
study using Altropane demonstrated that the patient did not in fact have
Parkinson's Disease.
Item 8. Exhibits.
--------
The following Exhibits are filed as part of this Report on Form 8-K:
99.1 Press Release, dated July 16, 1996.
-2-
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BOSTON LIFE SCIENCES, INC.
Dated: July 19, 1996 By:/s/ Marc E. Lanser, M.D.
--------------------------------
Marc E. Lanser, M.D.,
Executive Vice President
and Chief Scientific Officer
-3-
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Exhibit No. Page
- ----------- ----
99.1 Press Release, dated July 16, 1996 5
<PAGE>
Exhibit 99.1
***FOR IMMEDIATE RELEASE***
BOSTON LIFE SCIENCES ANNOUNCES RESULTS OF
PHASE I/II STUDY ON ALTROPANE(TM)
Boston, MA - July 16, 1996 - Boston Life Sciences, Inc. (Nasdaq: BLSI) announced
that a physician-sponsored Phase I/II study on its Parkinson's Disease
diagnostic agent, Altropane, was complete. In the Phase I portion of the study,
Altropane was administered to ten healthy normal volunteers in order to
determine safety and brain image quality. The Phase II portion of the study was
designed to test Altropane's ability to detect changes in the number of dopamine
transporters in the brain in nine patients with clinically diagnosed Parkinson's
Disease. The study was carried out at the Massachusetts General Hospital under
the auspices of Dr. Alan Fishman, chief of nuclear medicine at the MGH.
"The results from this study show that Altropane is a safe, accurate, and
convenient agent to image the dopamine transporter system in the brain.
Quantitative data on the number of dopamine transporters in the affected region
of the brain can be obtained within 90 minutes of injection", said Marc E.
Lanser, MD, chief scientific officer of BLSI. "In this study, the use of
Altropane together with SPECT brain scanning demonstrated a greater than 70%
loss of dopamine transporters in patients with mild clinical disease. Patients
with more severe disease were shown to have had an even greater loss. In one
patient in whom the diagnosis of Parkinson's Disease was in dispute, physicians
using Altropane demonstrated that the patient did not in fact have Parkinson's
Disease. These gratifying results will enable us to move forward with the
clinical development program with great confidence."
BLSI is developing novel treatments for cancer, autoimmune diseases, and central
nervous system disorders. BLSI's products in pre-clinical development or in
clinical trials include, among others, THERAFECTIN/R/ (amiprilose HCI), a
potential treatment for rheumatoid arthritis; Cartilage-derived Inhibitor (CDI),
a natural anti-angiogenesis factor to treat solid tumors; Axogenesis Factor 1
(AF-1), a novel central nervous system growth factor; and transcription factors
that controls the expression of molecules associated with autoimmune disease and
allergies.
For further information contact:
Marc E. Lanser, M.D.
Chief Scientific Office
617-425-0200
